Nuvation Bio (NUVB)
(Delayed Data from NYSE)
$2.41 USD
+0.07 (2.99%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $2.41 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
F Value C Growth D Momentum F VGM
Brokerage Reports
0 items in cart
Nuvation Bio Inc. [NUVB]
Reports for Purchase
Showing records 1 - 20 ( 68 total )
Company: Nuvation Bio Inc.
Industry: Unclassified
Company: Nuvation Bio Inc.
Industry: Unclassified
Company: Nuvation Bio Inc.
Industry: Unclassified
Company: Nuvation Bio Inc.
Industry: Unclassified
TRUST-II in Taletrectinib Ahead of Pooled Data at ESMO
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Nuvation Bio Inc.
Industry: Unclassified
Company: Nuvation Bio Inc.
Industry: Unclassified
Biotechnology-Monthly Check-Up- September 2024
Provider: Wedbush Securities Inc.
Analyst: Research Department
Company: Nuvation Bio Inc.
Industry: Unclassified
Company: Nuvation Bio Inc.
Industry: Unclassified
Company: Nuvation Bio Inc.
Industry: Unclassified
Company: Nuvation Bio Inc.
Industry: Unclassified
Company: Nuvation Bio Inc.
Industry: Unclassified
Company: Nuvation Bio Inc.
Industry: Unclassified
Company: Nuvation Bio Inc.
Industry: Unclassified
Taletrectinib Granted Orphan Drug Designation; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Nuvation Bio Inc.
Industry: Unclassified
Company: Nuvation Bio Inc.
Industry: Unclassified
Key Takeaways for ASCO 2024; Roundup for Covered Companies (Pt. 2)
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Nuvation Bio Inc.
Industry: Unclassified
TRUST-I Data Released; Taletrectinib Looking Better and Better; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Nuvation Bio Inc.
Industry: Unclassified
Company: Nuvation Bio Inc.
Industry: Unclassified
Company: Nuvation Bio Inc.
Industry: Unclassified
Company: Nuvation Bio Inc.
Industry: Unclassified
Updated Taletrectinib Data Expected at ASCO; 1Q24 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R